Alignment Healthcare stock slides 16% as legal investigators probe claims of manipulated EBITDA metrics used to boost executive pay.
Alignment Healthcare, Inc. is facing a securities fraud investigation initiated by BFA Law regarding allegations that the company and its senior executives artificially inflated adjusted EBITDA metrics. This manipulation was allegedly performed to boost executive compensation packages, leading to a significant 16% decline in the company's stock price following the news.
The company is being investigated for allegedly inflating adjusted EBITDA to increase executive compensation.
The stock price dropped by 16% following the announcement of the investigation.
Alignment Healthcare shares tumbled 16% following the announcement of a securities fraud investigation by BFA Law. The probe centers on allegations that senior executives artificially inflated adjusted EBITDA figures to secure higher compensation packages.
BFA Law is investigating claims that the company and its executives artificially inflated adjusted EBITDA metrics to boost executive compensation.
Alignment Healthcare shares fell 16% following the public disclosure of the investigation.